Table 1. Characteristics of the participants.
| Characteristic | FAS (n=638) |
|---|---|
| Sex, n (%) | |
| Male | 200 (31.3) |
| Female | 437 (68.5) |
| Missing | 1 (0.2) |
| Age, mean ± SD | 55.7 (12.23) |
| Age group, n (%) | |
| <65 | 466 (73.0) |
| ≥65 | 170 (26.6) |
| Missing | 2 (0.4) |
| ECOG PS, n (%) | |
| 0–1 | 589 (92.3) |
| ≥2 | 4 (0.6) |
| Missing | 45 (7.1) |
| Prior G-CFS, n (%) | |
| Yes | 142 (22.3) |
| No | 493 (77.3) |
| Missing | 3 (0.4) |
| Prophylaxis strategy, n (%) | |
| Primary | 493 (77.3) |
| Secondary | 142 (22.3) |
| Missing | 3 (0.4) |
| Radiotherapy history, n (%) | |
| Yes | 66 (10.3) |
| No | 566 (88.7) |
| Missing | 6 (1.0) |
| Cycle length, n (%) | |
| 1 week | 20 (3.1) |
| 2 weeks | 41 (6.4) |
| 3 weeks | 407 (63.8) |
| 4 weeks | 14 (2.3) |
| Missing | 156 (24.4) |
| Study drug dosage, n (%) | |
| Fixed dosage (6 mg) | 626 (98.1) |
| Weight-adjusted dosage (100 μg/kg) | 12 (1.9) |
| Cancer type, n (%) | |
| Solid tumor: | |
| Breast cancer | 323 (50.6) |
| Colorectal cancer | 51 (8.0) |
| Non-small cell lung cancer | 43 (6.7) |
| Gastric cancer | 35 (5.5) |
| Small cell lung cancer | 33 (5.2) |
| Esophageal cancer | 22 (3.4) |
| Ovarian cancer | 16 (2.5) |
| Pancreatic cancer | 13 (2.0) |
| Nasopharyngeal cancer | 9 (1.4) |
| Cervical cancer | 7 (1.1) |
| Head and neck cancer | 4 (0.6) |
| Hematological tumor: | |
| DLBCL | 9 (1.4) |
| Other B-cell lymphoma | 6 (0.9) |
| T-cell lymphoma | 3 (0.5) |
| Others | 5 (0.8) |
| Cancer stage | |
| I | 32 (5.1) |
| II | 133 (20.8) |
| III | 133 (20.8) |
| IV | 137 (21.5) |
| Missing | 209 (32.8) |
ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set; G-CFS, granulocyte colony-stimulating factor; DLBCL, diffused large-B cell lymphoma.